Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · M-M-RVaxPro
M-M-RvaxPro powder and solvent for suspension for injection M-M-RvaxPro powder and solvent for suspension for injection in pre-filled syringe Measles, mumps and rubella vaccine (live) · Abschnitt 4.8 · PDF-Seite 7
HOS-114026 · Präparat HOS-094015
In a clinical trial, 752 children received M-M-RvaxPro, either intramuscularly or subcutaneously. The
general safety profile of either administration routes were comparable, although injection site reactions
were less frequent in the IM group (15.8%) compared with the SC group (25.8%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-30T16:34:00Z · SHA-256 1f84b715b09e24aaf9cb7a48ff222d83aa13b8cc05114993c41c6a61cefc89b7 · Passage 81934a038f9a640d89d03f1dc2ae3c4d780b4b44a7608fdd10e5077820315815 · Zeichen 257–543 im Abschnitt
Nebenwirkungen · M-M-RVaxPro
M-M-RvaxPro powder and solvent for suspension for injection M-M-RvaxPro powder and solvent for suspension for injection in pre-filled syringe Measles, mumps and rubella vaccine (live) · Abschnitt 4.8 · PDF-Seite 7
HOS-114027 · Präparat HOS-094015
All adverse reactions were evaluated in 1 940 children. Among these children, the vaccine-related
adverse reactions, summarised in section b, were observed in individuals following vaccination with
M-M-RvaxPro (excluding isolated reports with frequency < 0.2%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-30T16:34:00Z · SHA-256 1f84b715b09e24aaf9cb7a48ff222d83aa13b8cc05114993c41c6a61cefc89b7 · Passage 99b0fd20fed79c256ecccff04d40333c984cc2277b04f6a3e700b9f0951b6041 · Zeichen 545–806 im Abschnitt
Nebenwirkungen · M-M-RVaxPro
M-M-RvaxPro powder and solvent for suspension for injection M-M-RvaxPro powder and solvent for suspension for injection in pre-filled syringe Measles, mumps and rubella vaccine (live) · Abschnitt 4.8 · PDF-Seite 7
HOS-114028 · Präparat HOS-094015
In comparison to the first dose, a second dose of M-M-RvaxPro is not associated with an increase in
the incidence and severity of clinical symptoms including those suggestive of hypersensitivity
reaction.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-30T16:34:00Z · SHA-256 1f84b715b09e24aaf9cb7a48ff222d83aa13b8cc05114993c41c6a61cefc89b7 · Passage cfc05c612427d1ce324d495486e60a66b6ad5850864b93c3833e446756873275 · Zeichen 808–1012 im Abschnitt
Nebenwirkungen · M-M-RVaxPro
M-M-RvaxPro powder and solvent for suspension for injection M-M-RvaxPro powder and solvent for suspension for injection in pre-filled syringe Measles, mumps and rubella vaccine (live) · Abschnitt 4.8 · PDF-Seite 7
HOS-114029 · Präparat HOS-094015
Additionally, other adverse reactions reported with post-marketing use of M-M-RvaxPro and/or in
clinical studies and post-marketing use of previous formulations of monovalent and of the combined
measles, mumps and rubella vaccines manufactured by MSD without regard to causality or frequency
are available and are summarised in section b. The frequency of these adverse events is qualified as
"not known" when it cannot be estimated based on the available data. These data were reported based
on more than 400 million doses distributed worldwide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-30T16:34:00Z · SHA-256 1f84b715b09e24aaf9cb7a48ff222d83aa13b8cc05114993c41c6a61cefc89b7 · Passage ae855e13857fa701de90a037e5074dd0defb7d76213513efd3b355f50443dace · Zeichen 1014–1560 im Abschnitt
Nebenwirkungen · M-M-RVaxPro
M-M-RvaxPro powder and solvent for suspension for injection M-M-RvaxPro powder and solvent for suspension for injection in pre-filled syringe Measles, mumps and rubella vaccine (live) · Abschnitt 4.8 · PDF-Seite 7
HOS-114030 · Präparat HOS-094015
The most common adverse reactions reported with the use of M-M-RvaxPro were: fever (38.5 °C or
higher); injection site reactions including pain, swelling and erythema.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-30T16:34:00Z · SHA-256 1f84b715b09e24aaf9cb7a48ff222d83aa13b8cc05114993c41c6a61cefc89b7 · Passage 51413b44120d9e2415da2bc23014ce4d346b06719a00345ab0b13268a05ea0ae · Zeichen 1562–1729 im Abschnitt
Nebenwirkungen · M-M-RVaxPro
M-M-RvaxPro powder and solvent for suspension for injection M-M-RvaxPro powder and solvent for suspension for injection in pre-filled syringe Measles, mumps and rubella vaccine (live) · Abschnitt 4.8 · PDF-Seite 7
HOS-114031 · Präparat HOS-094015
b. Tabulated list of adverse reactions
Adverse reactions are ranked under headings of frequency using the following convention:
[Very common (≥ 1/10); Common (≥ 1/100 to < 1/10); Uncommon (≥ 1/1 000 to < 1/100); Not known
(cannot be estimated from the available data)]
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-30T16:34:00Z · SHA-256 1f84b715b09e24aaf9cb7a48ff222d83aa13b8cc05114993c41c6a61cefc89b7 · Passage 3adde4371a8b5e0587b7dd253c6f5464d01f5c39c23f4de9613d5ab60bc8476d · Zeichen 1731–1999 im Abschnitt
Nebenwirkungen · M-M-RVaxPro
M-M-RvaxPro powder and solvent for suspension for injection M-M-RvaxPro powder and solvent for suspension for injection in pre-filled syringe Measles, mumps and rubella vaccine (live) · Abschnitt 4.8 · PDF-Seite 7
HOS-114032 · Präparat HOS-094015
Adverse reactions Frequency
Infections and infestations
Nasopharyngitis, Upper respiratory tract infection or
Uncommon
Viral infection
Aseptic meningitis†, Atypical measles, Epididymitis,
Orchitis, Otitis media, Parotitis, Rhinitis, Subacute Not known
sclerosing panencephalitis†
Blood and the lymphatic system disorders
Regional lymphadenopathy, Thrombocytopenia Not known
Immune system disorders
Anaphylactoid reaction, Anaphylaxis and related
phenomenon such as Angioneurotic oedema, Facial Not known
oedema, and Peripheral oedema
Psychiatric disorders
Crying Uncommon
Irritability Not known
Nervous system disorders
Afebrile convulsions or seizures, Ataxia, Dizziness,
Encephalitis†, Encephalopathy†, Febrile convulsion (in
children), Guillain-Barre syndrome, Headache, Not known
Measles inclusion body encephalitis (MIBE) (see
section 4.3), Ocular palsies, Optic neuritis,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-30T16:34:00Z · SHA-256 1f84b715b09e24aaf9cb7a48ff222d83aa13b8cc05114993c41c6a61cefc89b7 · Passage 5f4f0c888273df86f91de062d96e34a978e60871b606d0675124b1b5fbd6af1f · Zeichen 2023–3182 im Abschnitt
Nebenwirkungen · M-M-RVaxPro
M-M-RvaxPro powder and solvent for suspension for injection M-M-RvaxPro powder and solvent for suspension for injection in pre-filled syringe Measles, mumps and rubella vaccine (live) · Abschnitt 4.8 · PDF-Seite 7–8
HOS-114033 · Präparat HOS-094015
7
Paraesthesia, Polyneuritis, Polyneuropathy,
Retrobulbar neuritis, Syncope
Eye disorders
Conjunctivitis, Retinitis Not known
Ear and labyrinth disorders
Nerve deafness Not known
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea Uncommon
Bronchial spasm, Cough, Pneumonia, Pneumonitis
Not known
(see section 4.3), Sore throat
Gastrointestinal disorders
Diarrhoea or Vomiting Uncommon
Nausea Not known
Skin and subcutaneous tissue disorders
Rash morbilliform or other Rash Common
Urticaria Uncommon
Panniculitis, Pruritus, Purpura, Skin induration,
Stevens-Johnson syndrome, Skin granuloma Not known
(associated with vaccine derived rubella virus)
Musculoskeletal, connective tissue and bone disorders
Arthritis† and/or Arthralgia† (usually transient and
Not known
rarely chronic), Myalgia
General disorders and administration site conditions
Fever (38.5 °C or higher), Injection site erythema,
Very common
Injection site pain, and Injection site swelling
Injection site bruising Common
Injection site rash Uncommon
Burning and/or Stinging of short duration at the
injection site, Malaise, Papillitis, Peripheral oedema,
Not known
Swelling, Tenderness, Vesicles at the injection site,
Wheal and Flare at the injection site
Vascular disorders
Vasculitis Not known
†
see section c
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-30T16:34:00Z · SHA-256 1f84b715b09e24aaf9cb7a48ff222d83aa13b8cc05114993c41c6a61cefc89b7 · Passage 85636901618a69f6d6b116e9414b088beccbb0bc8626b3b2b48b0ed019800683 · Zeichen 3237–5376 im Abschnitt
Nebenwirkungen · M-M-RVaxPro
M-M-RvaxPro powder and solvent for suspension for injection M-M-RvaxPro powder and solvent for suspension for injection in pre-filled syringe Measles, mumps and rubella vaccine (live) · Abschnitt 4.8 · PDF-Seite 8
HOS-114034 · Präparat HOS-094015
c. Description of selected adverse reactions
Aseptic meningitis
Cases of aseptic meningitis have been reported following measles, mumps and rubella vaccination.
Although a causal relationship between other strains of mumps vaccine and aseptic meningitis has
been shown, there is no evidence to link Jeryl Lynn mumps vaccine to aseptic meningitis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-30T16:34:00Z · SHA-256 1f84b715b09e24aaf9cb7a48ff222d83aa13b8cc05114993c41c6a61cefc89b7 · Passage c01f2d950b065ec38a84e12b4dbad8d9cbe08677811d2eed8d07e51e70672f1d · Zeichen 5378–5724 im Abschnitt
Nebenwirkungen · M-M-RVaxPro
M-M-RvaxPro powder and solvent for suspension for injection M-M-RvaxPro powder and solvent for suspension for injection in pre-filled syringe Measles, mumps and rubella vaccine (live) · Abschnitt 4.8 · PDF-Seite 8
HOS-114035 · Präparat HOS-094015
Encephalitis and Encephalopathy
In severely immunocompromised individuals inadvertently vaccinated with measles-containing
vaccine, measles inclusion body encephalitis, pneumonitis, and fatal outcome as a direct consequence
of disseminated measles vaccine virus infection have been reported (see section 4.3); disseminated
mumps and rubella vaccine virus infection has also been reported.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-30T16:34:00Z · SHA-256 1f84b715b09e24aaf9cb7a48ff222d83aa13b8cc05114993c41c6a61cefc89b7 · Passage 7934bfdd3ba2bb171ea44f3d067675317c12f7826f069aba92f868fdaf419a3c · Zeichen 5726–6114 im Abschnitt
Nebenwirkungen · M-M-RVaxPro
M-M-RvaxPro powder and solvent for suspension for injection M-M-RvaxPro powder and solvent for suspension for injection in pre-filled syringe Measles, mumps and rubella vaccine (live) · Abschnitt 4.8 · PDF-Seite 8
HOS-114036 · Präparat HOS-094015
Subacute sclerosing panencephalitis
There is no evidence that measles vaccine can cause subacute sclerosing panencephalitis (SSPE).
There have been reports of SSPE in children who did not have a history of infection with wild-type
measles but did receive measles vaccine. Some of these cases may have resulted from unrecognised
measles in the first year of life or possibly from the measles vaccination. The results of a retrospective
case-controlled study conducted by the US Centers for Disease Control and Prevention suggest that
the overall effect of measles vaccine has been to protect against SSPE by preventing measles with its
inherent risk of SSPE.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-30T16:34:00Z · SHA-256 1f84b715b09e24aaf9cb7a48ff222d83aa13b8cc05114993c41c6a61cefc89b7 · Passage 890be11828fc743d28130b8a9d66a2644b15b6ff7f6cb1292187ebd0c23cf710 · Zeichen 6116–6773 im Abschnitt
Nebenwirkungen · M-M-RVaxPro
M-M-RvaxPro powder and solvent for suspension for injection M-M-RvaxPro powder and solvent for suspension for injection in pre-filled syringe Measles, mumps and rubella vaccine (live) · Abschnitt 4.8 · PDF-Seite 8–9
HOS-114037 · Präparat HOS-094015
8
Arthralgia and/or arthritis
Arthralgia and/or arthritis (usually transient and rarely chronic), and polyneuritis are features of
infection with wild-type rubella and vary in frequency and severity with age and sex, being greatest in
adult females and least in prepubertal children. Following vaccination in children, reactions in joints
are generally uncommon (0-3%) and of brief duration. In women, incidence rates for arthritis and
arthralgia are generally higher than those seen in children (12-20%), and the reactions tend to be more
marked and of longer duration. Symptoms may persist for a matter of months or on rare occasions for
years. In adolescent girls, the reactions appear to be intermediate in incidence between those seen in
children and adult women. Even in older women (35-45 years), these reactions are generally well
tolerated and rarely interfere with normal activities.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-30T16:34:00Z · SHA-256 1f84b715b09e24aaf9cb7a48ff222d83aa13b8cc05114993c41c6a61cefc89b7 · Passage baa9aa3b70fc7e8bb87d3f9569770721f3372cf0b9a6bd8c32248c8bb879dec0 · Zeichen 6834–7728 im Abschnitt
Nebenwirkungen · M-M-RVaxPro
M-M-RvaxPro powder and solvent for suspension for injection M-M-RvaxPro powder and solvent for suspension for injection in pre-filled syringe Measles, mumps and rubella vaccine (live) · Abschnitt 4.8 · PDF-Seite 9
HOS-114038 · Präparat HOS-094015
Chronic arthritis
Chronic arthritis has been associated with wild-type rubella infection and has been related to persistent
virus and/or viral antigen isolated from body tissues. Only rarely have vaccine recipients developed
chronic joint symptoms.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-30T16:34:00Z · SHA-256 1f84b715b09e24aaf9cb7a48ff222d83aa13b8cc05114993c41c6a61cefc89b7 · Passage c822e39669833a90c5525f53bc5d5105ebc17b8170809f608cdba226b18233ea · Zeichen 7730–7978 im Abschnitt
Nebenwirkungen · M-M-RVaxPro
M-M-RvaxPro powder and solvent for suspension for injection M-M-RvaxPro powder and solvent for suspension for injection in pre-filled syringe Measles, mumps and rubella vaccine (live) · Abschnitt 4.8 · PDF-Seite 9
HOS-114039 · Präparat HOS-094015
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system
listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-30T16:34:00Z · SHA-256 1f84b715b09e24aaf9cb7a48ff222d83aa13b8cc05114993c41c6a61cefc89b7 · Passage 42f7144177697b690f59b1bda795c3fd216297691cf296a2e1269a137feab3cd · Zeichen 7980–8335 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.